The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 96K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dyall, R.
Right arrow Articles by Nikolic-Zugic, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dyall, R.
Right arrow Articles by Nikolic-Zugic, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1998/11/1553/ $5.00
The Journal of Experimental Medicine, Volume 188, Number 9, November 2, 1998 1553-1561

Articles

Heteroclitic Immunization Induces Tumor Immunity

Ruben Dyall*, Wilbur B. Bowne{ddagger}, Lawrence W. Weber{ddagger}, Joel LeMaoult*, Paul Szabo§, Yoichi Moroi{ddagger}, Gregory Piskun{ddagger}, Jonathan J. Lewis{ddagger}, Alan N. Houghton{ddagger}, and Janko Nikolic-Zugic*

From the * T Cell Development Laboratory and the {ddagger} Swim Across America Laboratory, Immunology Program, Memorial Sloan-Kettering Cancer Center, New York 10021; and the § Division of Geriatrics and Gerontology, Cornell University Medical College, New York 10021

In tumor transplantation models in mice, cytotoxic T lymphocytes (CTLs) are typically the primary effector cells. CTLs recognize major histocompatibility complex (MHC) class I–associated peptides expressed by tumors, leading to tumor rejection. Peptides presented by cancer cells can originate from viral proteins, normal self-proteins regulated during differentiation, or altered proteins derived from genetic alterations. However, many tumor peptides recognized by CTLs are poor immunogens, unable to induce activation and differentiation of effector CTLs. We used MHC binding motifs and the knowledge of class I:peptide:TCR structure to design heteroclitic CTL vaccines that exploit the expression of poorly immunogenic tumor peptides. The in vivo potency of this approach was demonstrated using viral and self-(differentiation) antigens as models. First, a synthetic variant of a viral antigen was expressed as a tumor antigen, and heteroclitic immunization with peptides and DNA was used to protect against tumor challenge and elicit regression of 3-d tumors. Second, a peptide from a relevant self-antigen of the tyrosinase family expressed by melanoma cells was used to design a heteroclitic peptide vaccine that successfully induced tumor protection. These results establish the in vivo applicability of heteroclitic immunization against tumors, including immunity to poorly immunogenic self-proteins.

Key Words: cytotoxic T lymphocyte • tumors • peptide vaccines • heteroclitic peptides • major histocompatibility complex class I

Address correspondence to Janko Nikolic-Zugic, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 98, New York, NY 10021. Phone: 212-639-2387; Fax: 212-794-4019; E-mail: nikolicj{at}mskcc.org; or A.N. Houghton, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. Phone: 212-639-7595; Fax: 212-794-4352; E-mail: a-houghton{at}ski.mskcc.org

Abbreviations used: ER, endoplasmic reticulum; ERIS, ER insertion sequence; pCTL, precursor CTL; SEI, peptide SEIEFARL, a variant of SSI; SSI, Herpes simplex virus glycoprotein B498–505 peptide SSIEFARL; TAY, peptide TAYRYHLL, an engineered variant of TWH; TM, synthetic adjuvant TiterMax; TWH, melanoma gp75222–229 peptide, TWHRYHLL.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS